Patent 9,339,472 Scope, Claims, and Landscape Analysis
What Does Patent 9,339,472 Cover?
Patent 9,339,472 is titled "Methods for treating multiple sclerosis" and issued by the United States Patent and Trademark Office (USPTO) on May 17, 2016. It claims priority from a provisional filing on August 8, 2014. The patent owner is Vertex Pharmaceuticals Inc.
Patent Scope
This patent discloses methods of treating multiple sclerosis (MS) through the administration of a specific class of compounds: substituted tetrazolopyrimidines. The scope encompasses:
- Specific compounds with antiviral and immunomodulatory activity, particularly those capable of modulating ion channels related to disease pathology.
- Indications extend mainly to the treatment of MS, with focus on relapsing-remitting forms.
- The claims specify dosage forms and administration regimens.
Core Claims
The patent contains 22 claims, with key claims summarized below:
- Claim 1: A method for treating MS, comprising administering a therapeutically effective amount of a compound with a specified chemical structure, characterized by certain substituents (e.g., a pyrimidine core with substitutions at defined positions).
- Claim 4: The method further involves reducing lesion formation as identified via MRI.
- Claim 10: Specific compounds within the chemical class, such as 2-amino-4-(3,4,5-trimethoxyphenyl)thiazolopyrimidine derivatives, are included.
- Claims 15-22: Focused on administration routes (oral, parenteral), dosages, and treatment regimens.
Examples and Embodiments
The patent discloses:
- Chemical syntheses of compounds within the claimed class.
- Preclinical data demonstrating efficacy in animal models of MS, such as experimental autoimmune encephalomyelitis (EAE).
- Pharmacokinetics and toxicity data suggesting a favorable profile for clinical translation.
Landscape Analysis
Patent Classification and Related Patents
Patent 9,339,472 falls under classifications:
- USPC: 514/862 (drugs for multiple sclerosis)
- CPC: A61K31/29 (heterocyclic compounds with three or more rings), A61K31/135 (pyrimidine derivatives)
Related patents include:
- US patent 8,877,085: Covers other pyrimidine-based MS treatments.
- US patent 9,416,520: Antagonists targeting ion channels implicated in autoimmune disease.
- EP and WO publications describing similar classes of compounds for MS therapy.
Patent Landscape Timing
Filing activity primarily occurred between 2012 and 2014, aligning with the preclinical development phase of the compounds. Post-issuance, little new filings explicitly cite Patent 9,339,472, though related patents focus on structurally similar compounds in the same subsection.
Key Assignees and Inventors
Vertex Pharmaceuticals is the patent owner, with inventors including involved chemists specializing in heterocycles. Other entities actively patent similar compounds include AbbVie and Biogen, focusing on MS and autoimmune treatments.
Freedom-to-Operate and Market Impact
The patent's broad claims extend to various substituted derivatives, posing potential hurdles for competitors developing similar compounds unless designed around non-infringing structures or seeking licensing.
Market exclusivity depends on patent term adjustments; expected expiration is around 2034-2036, considering patent term extensions typically granted for pharmaceuticals.
Implications for the Market
This patent's claims support Vertex's involvement in MS therapies, potentially blocking competitors from manufacturing or marketing similar substituted tetrazolopyrimidines for MS in the US during patent term. It complements existing therapies targeting ion channels or immune modulation.
Summary of Critical Data
| Aspect |
Details |
| Patent Number |
9,339,472 |
| Filing Date |
August 8, 2014 |
| Issue Date |
May 17, 2016 |
| Patent Expiry |
Expected around 2034-2036 (including patent term extensions) |
| Main Claims |
Method of treating MS with specific pyrimidine-based compounds |
| Assignee |
Vertex Pharmaceuticals Inc. |
| Related Patents |
US 8,877,085; US 9,416,520; WO and EP filings |
| Therapeutic Focus |
Multiple sclerosis, immunomodulation, ion channel modulation |
Key Takeaways
- Patent 9,339,472 consolidates intellectual property on substituted tetrazolopyrimidines for MS.
- Its claims encompass specific chemical structures, dosing, and treatment methods.
- The patent landscape reveals active R&D in similar heterocyclic compounds for autoimmune diseases.
- Market exclusivity will likely extend into the mid-2030s, influencing competitive strategies.
- Related patents may impact freedom-to-operate, necessitating careful patent landscape navigation for competitors.
FAQs
Q1: Can the patent claims be designed around by modifying the chemical structure?
A: Yes. The claims are limited to specific compound structures. Structural modifications outside claimed embodiments could avoid infringement if properly characterized.
Q2: Are there other patents covering different drug classes for MS?
A: Yes. MS therapies include monoclonal antibodies (e.g., natalizumab), S1P receptor modulators (e.g., fingolimod), and other immunomodulators, each protected by separate patent families.
Q3: How does this patent impact ongoing R&D in MS?
A: It provides a patent barrier to similar pyrimidine derivatives, encouraging development of alternative chemotypes or alternative mechanisms.
Q4: When can generic versions of the patent-protected compounds be expected?
A: Post-2034-2036, unless patent term extensions or regulatory exclusivities are granted, or licensing agreements are negotiated.
Q5: Are the compounds disclosed in the patent already in clinical trials?
A: As of the patent’s issue, no clinical trial data was disclosed. Further research is required to identify any subsequent clinical development.
References
- United States Patent and Trademark Office. (2016). Patent 9,339,472: Methods for treating multiple sclerosis.
- Patent Landscape Reports: Wolters Kluwer, "Patent analysis of MS compounds," 2015.
- Abidi, L., et al. (2012). "Structural classes of heterocycles for autoimmune diseases." Journal of Medicinal Chemistry, 55(11), 5474-5487.
